ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

Is Bevacizumab Effective for Reducing Epistaxis in Hereditary Hemorrhagic Telangiectasia?

by Christopher J. Chin, MD • September 24, 2017

  • Tweet
  • Email
Print-Friendly Version

TRIO Best PracticeTRIO Best Practice articles are brief, structured reviews designed to provide the busy clinician with a handy outline and reference for day-to-day clinical decision making. The ENTtoday summaries below include the Background and Best Practice sections of the original article. To view the complete Laryngoscope articles free of charge, visit Laryngoscope.;

You Might Also Like

  • Bevacizumab Therapy Effective for Hereditary Hemorrhagic Telangiectasia
  • Avastin Treatment for Hereditary Hemorrhagic Telangiectasia Epistaxis
  • Epistaxis Severity in Pediatric HHT Patients Is Typically Mild
  • Systemic Bevacizumab Promising for Treatment-Resistant Recurrent Respiratory Papillomatosis
Explore This Issue
September 2017

Background

Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, often manifests with epistaxis. The disease spectrum is wide; some patients have small, irritating bleeds, whereas other patients require monthly blood transfusions. There are many medical and surgical interventions for epistaxis in HHT, but none have been established as a gold-standard treatment. Bezaciumab (Avastin) is a vascular endothelial growth factor inhibitor. It has been used in various medical conditions, including neurofibromatosis 2 and metastatic colon cancer. Recently, it has been used in HHT as an agent to reduce epistaxis. It can be delivered intranasally (either topically or via submucosal injection) or systemically via intravenous. This review will summarize the most recent and topical evidence for bevacizumab in HHT and aim to answer the question: Is intranasal bevacizumab effective for reducing epistaxis in HHT?

Best Practice

Based on the current evidence, bevacizumab appears to be effective in reducing epistaxis in the HHT patient population. However, it should be noted that the existing literature is limited by small sample sizes and retrospective designs. Due to the rarity of this condition, a multicenter study would be ideal to help confirm these findings and ensure that the study is powered adequately. As well, further research comparing bevacizumab to the other existing therapies are needed to determine superiority (or inferiority) (Laryngoscope. 2017;127:289–290).

Filed Under: Practice Focus, Rhinology, Rhinology, TRIO Best Practices Tagged With: epistaxis, hereditary hemorrhagic telangiectasia, Osler-Weber-Rendu syndromeIssue: September 2017

You Might Also Like:

  • Bevacizumab Therapy Effective for Hereditary Hemorrhagic Telangiectasia
  • Avastin Treatment for Hereditary Hemorrhagic Telangiectasia Epistaxis
  • Epistaxis Severity in Pediatric HHT Patients Is Typically Mild
  • Systemic Bevacizumab Promising for Treatment-Resistant Recurrent Respiratory Papillomatosis

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Vertigo in the Elderly: What Does It Mean?
    • Experts Delve into Treatment Options for Laryngopharyngeal Reflux
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Weaning Patients Off of PPIs
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Podcasts Becoming More Popular Method of Education for Otolaryngologists
    • How to Embrace Optimism in the Midst of the COVID-19 Pandemic
    • Tips on How to Approach Conversations with Patients about the COVID-19 Vaccine
    • Steps You Should Take to Protect Your Voice and Hearing During Telemedicine Sessions
    • Routine Postoperative Adjunct Treatments Unnecessary for Idiopathic Cerebrospinal Fluid Leaks

Polls

Have you spoken with your patients about receiving the COVID-19 vaccine?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2021 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.